AI assistant
USCOM LIMITED — Regulatory Filings 2009
Jun 21, 2009
65979_rns_2009-06-21_3d8badf3-1c6f-46a0-ba3e-ef6cdb2abe21.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [71 x 87] intentionally omitted <==
MARKET ANNOUNCEMENT
Further 24 USCOM units ordered by Spacelabs Healthcare
Monday, 22nd June 2009: Uscom (ASX Code: UCM) today informed shareholders of the receipt of orders for a further 24 USCOM 1A units from Spacelabs Healthcare. The 24 USCOM 1A devices are to be delivered over the next two months.
Uscom CEO, Mr. Paul Butler said “These orders further demonstrate the commitment of Spacelabs to distributing the USCOM 1A device and the sales opportunity they see, even in difficult times, as the technology gains traction around the world.”
Mr Rob Phillips, Executive Chairman and Director of Clinical Science said “Uscom and Spacelabs are continuing to develop global sales and marketing for the Uscom technology and working closely to ensure a successful partnership.”
About Uscom
Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.
The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).
Uscom Contacts
Paul Butler Chief Executive Officer Office: 02 9247 4144 [email protected]
Rob Phillips Executive Chairman Office: 02 9247 4144 [email protected]
www.uscom.com.au
Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090